Press Release

Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

August 21, 2020

Harbour BioMed
on WeChat

Back to list

Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

August 21, 2020
  • HBM’s Bispecific Antibody BCMA X CD3 (HBM7020) has a unique 2+1 format built by the proprietary fully human heavy chain only antibody derived from Harbour HCAb Mice®
  • HBM7020 shows potent tumor killing efficacy with limited cytokine release preclinically which suggests its significant therapeutic window


August, 21, 2020, Cambridge, MA, Rotterdam, NL, Suzhou, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody – BCMA x CD3 (HBM7020,) at the Cell engager Summit. HBM7020 was developed using HBM’s own HBICETM (HCAb Based Bispecific Immune Cell Engager) platform and has shown remarkable tumor killing with minimal cytokine response, which could translate in to a relatively efficacious and safe therapeutic. The data was presented in the form of E-poster at 14:50 EDT, on August 19th, 2020. The Cell Engager Summit 2020 took place virtually, from August 18th – August 20th,2020.



B-cell maturation antigen (BCMA), a surface marker highly expressed on malignant plasma cells of multiple myeloma (MM) patients, has been recognized as an ideal target for T-cell redirecting therapies. Currently, BCMA targeted therapies are still limited by their unresponsiveness in some patients, fast relapse, toxicity due to cytokine release syndrome(CRS), and short half-life etc. The off-shelf HBICETM BCMAxCD3 may overcome some of the limitations and become the new generation of therapeutics for multiple myeloma.



HBM7020 is a novel BCMA x CD3 bispecific antibody generated with HBM’s HBICETM  platform and is a highly efficacious BsAb to selectively deplete BCMA-positive MM cells with limited cytokine release.  It was designed as a “2+1” format, with one anti-CD3 binding domain which has optimized T cell stimulation activity and cynomolgus cross-reactivity, and two anti-BCMA binding domains which has improved selectivity to BCMA-positive MM cells. HBM7020 induced efficient tumor cell killing of BCMA-positive MM cells and reduced the risk of CRS (cytokine release syndrome) comparing to competitor’ BCMAx CD3 bispecific antibodies. HBM7020 represents potentially better therapeutics for MM patients and other BCMA positive tumors.




Poster Title:


HBICETM-based BCMA x CD3 Bispecific Antibody with Efficient Tumor Killing and Minimal Cytokine Release




About HBICETM Platform: A Unique, HCAb-Based Platform for Immune Cell Engaging



Our HCAb platform can generate diverse and stable fully human HCAbs and derived human VH single-domain moieties, enabling us to make novel multi-specific and multi-valent antibodies in simplified structures with relatively smaller molecule size and fewer number of polypeptide chains. Leveraging the technology know-how we accumulated on our HCAb, we have independently developed the HBICETM Platform, which focuses on generating highly differentiated HCAb-based immune cell engagers capable of delivering tumor-killing effects unachievable by combination therapies. As the only proven bispecific mechanism of action in oncology, immune cell engagers engage patients’ own immune cells to identified tumor-specific antigen cells, with the goal of activating the cytotoxic potential of immune cells to fight cancers. As compared with the other bispecific formats for immune cell engaging, we believe the bispecifics generated on HBICETM platform are able to meet more parameters determining clinical activity of bispecifics.



About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  


For further information, please refer to



Please click the link below for the full poster:

We warmly welcome all forms of collaboration. If interested, please contact:





Atul Deshpande PhD, MBA

Chief Strategy Officer and Head, US Ops.

Harbour BioMed

Phone: +1-908-210-3347


Media Contact:

Harbour BioMed Public Relations